PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cell Host Microbe. Author manuscript; available in PMC 2010 June 18.
Published in final edited form as:
PMCID: PMC2729653
NIHMSID: NIHMS110789

Common themes in the design and function of bacterial effectors

Summary

Central to the biology of many pathogenic bacteria are a number of specialized machines, known as type III, type IV or type VI protein secretion systems. These machines have specifically evolved to deliver bacterial “effector” proteins into host cells with the capacity to modulate a variety of cellular functions. The identification of the biochemical activities of many effector proteins, coupled with a better understanding of their potential contribution to pathogenesis, have revealed common themes in the evolutionary design and function of these remarkable bacterial proteins.

Keywords: bacterial pathogenesis, Type III, Type IV and Type VI secretion systems, pathogen evolution, host-pathogen interactions

Introduction

Many gram-negative bacteria that are pathogenic or symbiotic for plants, insects, or animals have evolved complex machines to transfer multiple bacterially-encoded proteins into eukaryotic cells. At least three different types of these machines have been described, which for historical reasons are referred to as type III, type IV, and type VI protein secretion systems (Christie et al., 2005; Filloux et al., 2008; Galan and Wolf-Watz, 2006). A great deal of attention has been devoted to the study of these machines because they are central to the pathogenesis of the bacterial pathogens that encode them. Proteins delivered by these machines have the capacity to module a variety of cellular functions and are collectively known as “effectors”. Effectors are distinct from bacterial “toxins”, which are also bacterial products that exert their function on living cells or organisms (Alouf, 2000). A unique property of toxins is that their toxic effects can be observed when exogenously added to living organisms or cells. In contrast, the term “effectors” should be reserved for molecules that require specialized multiprotein machines for their direct delivery into target cells. However, the distinction between toxins and effectors reflects more than just differences in their delivery mechanisms. Bacterial toxins usually have a single biochemical activity that directly exerts its effect on specific cellular targets. By contrast, effector proteins exert their specific function in concert with the activities of multiple other bacterial effectors delivered by the same machine. The activities of effector proteins are often subtle and more “tuned” to modulate cellular functions rather than to irreversible disrupt cellular homeostasis. In fact, the evolution of protein delivery machines such as type III, type IV, and type VI secretion systems may have been specifically driven by the need to deliver multiple proteins in a coordinated fashion to modulate complex cellular processes.

The study of effector proteins delivered by these specialized machines has provided remarkable insight not only into fundamental aspects of host/pathogen interactions but also into the basic biology of eukaryotic cells. Despite the diversity of activities associated with the different effector proteins, it is now evident that there are a number of common themes that characterize the function of these molecules. The common themes in the evolutionary design of these molecules will be the subject of this review. In addition, the significant challenges to the study of these effector proteins stemming from their unique properties will also be discussed. In discussing these general themes, I will be drawing from specific examples of effectors delivered by type III secretion systems (TTSS) since they are the best characterized. However, I believe that these principles are applicable to bacterial effector proteins delivered by other machines. The purpose of this article is not to comprehensively review the literature of type III secretion systems or bacterial effector proteins. Rather, the intent is to discuss a limited set of specific examples of TTSS effectors that best illustrate the existence of common principles in the design and function of bacterial effector proteins.

Mimicry of host cell proteins

TTSSs are encoded by many important pathogenic bacteria including Salmonella enterica serovars (e. g. S. Typhimurium, S. Typhi, etc.), Shigella spp., Yersinia spp., Chlamydia spp., Pseudomonas spp., Vibrio spp., Bordetella spp., and pathogenic strains of E. coli (Galan and Wolf-Watz, 2006). All of these bacteria have evolved complex and unique functional interfaces with eukaryotic cells, and their TTSSs are central components of these interfaces. A theme that has emerged over the last few years is that many TTSS effector proteins exert their function by mimicking activities of endogenous cellular proteins (Stebbins and Galán, 2001). Such mimicry can sometimes be detected at the level of the primary amino acid sequence. For example, some effectors share significant amino acid sequence similarity to eukaryotic cell proteins (e. g. protein kinases or phosphatases) (Galyov et al., 1993; Guan and Dixon, 1990). Therefore their potential biochemical activities can be simply predicted from primary amino acid sequence analysis, although the identification of the cellular targets of these activities most often requires specific experimentation. However, this straightforward mimicry is rarely observed among most bacterial effectors. In fact, many effectors faithfully mimic the activities of cellular proteins without detectable amino acid sequence similarity (Stebbins and Galán, 2001). In such cases, the activities of the effector proteins cannot be predicted from their amino acid sequence analysis or even from their proto atomic structures (i. e. the atomic structures of the effector proteins by themselves and not in complex with their targets). For example, some effector proteins target Rho-family GTPases by mimicking the activities of guanine nucleotide exchange factors (GEFs) or GTPase activating proteins (GAPs). Yet, there is nothing in their primary amino acid sequence that would suggest these activities. Such is the case for the S. Typhimurium TTSS effectors SopE and SptP, which are a GEF and a GAP, respectively, for Rac, Cdc42 and RhoG (Fu and Galán, 1999; Hardt et al., 1998a). The crystal structure of the effector/target protein complex shows conformational changes imposed by SopE on the nucleotide-binding region of Rac1 that are virtually identical to those imposed by an endogenous exchange factor such as Tiam1 (Fig. 1A) (Buchwald et al., 2002). However, to introduce those conformational changes on its targets, which are critical for the nucleotide exchange activity, SopE utilizes different chemistry than Tiam1. This finding indicates that, remarkably, evolution has found more than one mechanism to execute essentially the same biochemical activity. Likewise, the crystal structure of SptP alone does not suggest that it would have GAP activity. However, when viewed in complex with its target, its GAP activity can be clearly inferred (Fig. 1B) (Stebbins and Galán, 2000). In this case, however, SptP utilizes similar chemistry to that utilized by most eukaryotic cell GAPs, which involves the precise positioning of a critical arginine residue within the active site of the GTPase. Therefore, SopE and SptP can be considered “convergently evolved” mimics of their eukaryotic cell counterparts.

Figure 1
Structural mimicry in type III secreted effector proteins

Other examples of mimicry to modulate Rho-family GTPase function are even more subtle. For example, the E. coli TTSS effector EspF(U) mimics an autoinhibitory domain found within N-WASP (Cheng et al., 2008). Through this mimicry, EspF(U) activates N-WASP by competitively disrupting its autoinhibited state. In this sense, EspF(U) functionally mimics Cdc42, which activates N-WASP in a similar manner. Another example of subtle mimicry is a group of TTSS effectors, collectively known as the WxxxE family of effector proteins, which include the Shigella spp. effectors IpgB1 and IpgB2 and the S. Typhimurium effector SifA. These effectors trigger responses equivalent to those stimulated by activated Rho-family GTPases by mimicking the activated state of these small G proteins (Alto et al., 2006; Ohlson et al., 2008).

Other examples of mimicry are seen in TTSS effectors that target the ubiquitination machinery. Protein ubiquitination is a multistep enzymatic process that results in the addition of ubiquitin to internal lysine residues of the substrate protein (Glickman and Ciechanover, 2002). The process involves an ubiquitin-activating enzyme (E1), which transfers ubiquitin to a family of ubiquitin-conjugating enzymes (E2s). Ubiquitin-loaded E2s are then recruited to their substrates by a family of ubiquitin ligases (E3s), which play a critical role in substrate recognition. Some TTSS effectors, exemplified by S. Typhimurium SopA or Pseudomonas syringae AvrPtoB, mimic the RING- and HECT-domain type of E3 ubiquitin ligases, respectively (Fig. 1C) (Diao et al., 2008; Janjusevic et al., 2006). In contrast, a recently identified family of TTSS effector proteins with E3 ligase activity mimics the cysteine-based chemistry of HECT E3 ligases but share no structural similarity to any known eukaryotic cell E3 ligases (Fig. 1C) (Quezada et al., 2009; Singer et al., 2008 ; Zhu et al., 2008).

From the examples discussed here and others listed in Table 1, it is apparent that mimicry is emerging as one of the most common features in the function of TTSS effector proteins. In the context of the biology of most bacteria encoding TTSSs, mimicry appears to be a very suitable strategy to interact with the host because it usually leads to reversible modulation of cellular functions without overt harm to the target cell. Since this mimicry most often cannot be gleaned from the primary amino acid sequence or even from the proto crystal structures of the effectors, a number of bioinformatics or high throughput crystallographic approaches are of limited use in the study of TTSS effector proteins. Rather, in most cases the identification of their specific targets or even the solution of the atomic structures of the effector/target protein complexes is required to characterize their function.

Table 1
Examples of mimicry in type III secretion effectors

Covalent modifications of host cell proteins

A number of effector proteins exert their function by introducing covalent modification to target cellular proteins (Table 2). In some instances, these covalent modifications are reversible and presumably aimed at modulating cellular functions by transiently altering the activity of the cellular targets. Phosphorylation is one of the most common mechanisms of signal transduction utilized by eukaryotic cells. It is therefore not surprising that several TTSS effectors target this process to modulate cell function. For example, serine/threonine protein kinases have been identified in Shigella spp. (e. g. OspG) (Kim et al., 2005) and Yersinia spp. (e. g. YpkA /YopO) (Galyov et al., 1993). The Shigella OspG effector phophorylates host ubiquitin-conjugating enzymes to thwart innate immune responses (Kim et al., 2005). The Yersinia YpkA/YopO kinase phosphorylates Gαq thus inhibiting G-protein coupled receptor signaling (Navarro et al., 2007), although the significance of this activity for Yersinia spp. pathogenesis is unknown. In addition, several effectors with protein phosphatase activity have also been identified. This includes the Yersinia’s YopH and Salmonella’s SptP effectors, which disrupt macrophage function and MAP kinase signaling, respectively, by targeting several tyrosine-phosphorylated cellular proteins (Bliska and Black, 1995; Murli et al., 2001).

Table 2
Examples of covalent modifications introduced by type III secretion effectors

More recently, several effector proteins with enzymatic activities resulting in unusual covalent modification have been discovered. For example, a family of TTSS effectors, which include the Shigella spp. OspF and Salmonella SpvC proteins, were shown to inhibit MAP kinase signaling by an unusual post translational modification. This modification involves a phosphothreonine lyase enzymatic activity, which results in the irreversible removal of the phosphate group from phosphothreonine and its conversion into dehydrobutyrine (Li et al., 2007). This activity has not yet been described in eukaryotic cells. Another example of an unusual covalent modification associated with an effector is the Yersinia YopJ protein, which inhibits various signal transduction pathways by acetylating critical serine or threonine residues of a group of proteins belonging to the mitogen activated protein kinase kinases (MKK) family (Mukherjee et al., 2006). Since the MKKs are activated by phosphorylation of the same residues targeted by YopJ, the modified kinases cannot be activated. Protein acetylation is a well-characterized regulatory mechanism of eukaryotic cell histones. However, histone acetyl transferases in eukaryotic cells modify protein function by acetylating lysine residues. Therefore, YopJ is the first identified enzyme that acetylates serine and threonine residues, and it has been suggested that YopJ may well mimic a yet to be identified class of eukaryotic enzymes that may regulate signaling via acetylation. Another unusual covalent modification mediated by the TTSS effector protein VopS has been described in Vibrio parahaemolyticus (Yarbrough et al., 2009). This effector covalently modifies a conserved threonine residue on Rho, Rac, and Cdc42 by adding adenosine 5’-monophosphate (AMP), a process that has been referred to as “AMPylation”. AMPylated Rho GTPases are unable to interact with downstream effectors, thereby inhibiting actin dynamics in the infected cell. Interestingly, AMPylated proteins have also been detected in eukaryotic proteins in the absence of bacterial infection. Although it is still unclear whether these modifications are reversible, the finding of acetylated and AMPylated proteins within the host cell suggest that this may well be the case and that these post-translational modifications may be involved in cell signaling. These examples of novel activities associated with TTS effectors that may be present in eukaryotic cells showcase how the study of bacterial virulence factors may lead to important new insights into basic cell biology.

Work in concert with other effector proteins

One of the most daunting challenges in the study of TTSS effector proteins is the fact that they exert their function in the context of other effector proteins. Indeed, it can be argued that, in contrast to “toxins” (as defined above), TTSSs have evolved to modulate complex cellular functions in a manner that requires the coordinated activity of many effectors delivered in a precise temporal and spatial manner. For example, the Salmonella TTSS effector SptP is a GAP for several Rho-GTPase family members (Fu and Galán, 1999). Since one of the physiological roles of these small G proteins is to modulate actin dynamics, transient expression of SptP into mammalian cells leads to a profound change in the actin cytoskeleton. This observation led to the erroneous conclusion that the function of this effector was to disrupt the actin cytoskeleton presumably to prevent phagocytosis (Fu and Galán, 1998). However, subsequent studies showed that the function of SptP was indeed the opposite. In the context of other Salmonella effectors that have the capacity to activate Rho-family GTPases (e. g. the GEFs SopE and SopE2), the SptP GAP activity is required for the cells to recover homeostasis (Fu and Galán, 1999). Since profuse stimulation of Rho-family GTPases by the bacterial effectors is harmful to the cell, Salmonella evolved an effector to put a “brake” to such stimulation and thus preserve the integrity of the cell. This example clearly illustrates that the standard reductionist approaches commonly utilized in the field to study effector function (e. g. overexpression of single effectors within a cell) can lead to misinterpretation. To compound the challenge, TTSS effectors are usually delivered in very small amounts, which is in sharp contrast with many experimental approaches that result in a vast overexpression of a given effector within cells. Therefore, while the biochemical activities of many of TTSS effectors are known, the main challenge remains to identify their relevant cellular targets. In this regard, it will be essential to consider both the environment in which these effectors exert their function, and the concentration that they achieve within the cell during infection. Once these parameters are considered, it is possible that some of the targets that have thus far been identified using standard approaches may prove to be irrelevant.

Similar biochemical activity in a different bacteria/host interface results in unique effects

During the last few years, remarkable progress has been made in the identification of enzymatic activities associated with TTSS effector proteins, many of them discussed in this article. However, there has been much less progress in the understanding of the contribution of these activities to the host/pathogen interactions. Although the identification of the biochemical activity of a given effector is very helpful, it is certainly not sufficient to understand its potential role during infection. The identification of the physiological targets of those activities is essential to really understand effector function in the context of infection. As discussed above, TTSSs are central components of the host/pathogen interface. Given the great diversity in the pathogens that encode TTSS, the host/pathogen functional interface in which these systems participate varies considerably. Yet, apparently homologous effectors (i. e. effectors with the same biochemical activities) are encoded by very different pathogens. The differences between host/pathogen functional interfaces must be considered before extrapolating findings from homologous effectors encoded by different pathogens since it is possible that the same biochemical activity associated with such an effector may be directed to a different target or may result in a different effect. For example, some of these pathogens have evolved to gain access into host cells while others remain extracellular during their infection cycle. Salmonella spp. and Yersinia spp. are intracellular and extracellular pathogens, respectively, and yet, they encode several apparently homologous effectors. Yersinia YopE and Salmonella SptP are both GAPs for Rho-family GTPases (Fu and Galán, 1999; Von Pawel-Rammingen et al., 2000). Yet, while YopE disrupts the actin cytoskeleton to prevent bacterial phagocytosis, SptP, as discussed above, counters the activity of other effectors to restore cellular homeostasis and the integrity of the actin cytoskeleton. The acetyl transferases YopJ and AvrA encoded by Yersinia spp. and S. Typhimurium are another example of apparently homologous effectors carrying out different functions. While YopJ broadly inhibits all MAP kinase pathways and NF-κB signaling by targeting all MKKs and IKKβ (Orth, 2002), AvrA, when delivered in physiological amounts into eukaryotic cells, only targets the Jnk pathway (Du and Galan, 2009; Jones et al., 2008). Therefore it seems that evolution has shaped the activity of these highly related molecules to suit the functional interface of the respective pathogens that harbor them. In the case of Yersinia spp., an extracellular pathogen, YopJ has evolved to broadly inhibit the host innate immune response. In contrast, AvrA exerts a more subtle effect to presumably modulate but not prevent the transcriptional responses induced by Salmonella. The take home message of this common theme is that the context in which a given effector exerts its activity is crucial for the understanding of its function during infection.

Precise temporal regulation

As discussed above, the function of different effectors delivered by the same pathogen is exerted in the context of the activities of other effectors, ultimately resulting in the modulation or induction of highly coordinated and complex cellular responses. Therefore it is not surprising that the specific activity of individual effectors is highly regulated both temporally and spatially. There are several mechanisms involved in the temporal regulation of TTSS effector function. For example, although poorly understood at the mechanistic level, there is increasing evidence that there is a “hierarchy” in the engagement of TTSS effectors by the protein delivery machine (Collazo and Galán, 1996; Deng et al., 2005; Sorg et al., 2006; Wang et al., 2008). It is therefore possible that this mechanism may be central for the temporal coordination of the delivery of groups of effector proteins, particularly if these effectors must be delivered in a hierarchical fashion over a short period of time.

In addition, some pathogens encode more than one TTSS that are expressed at different times during infection and are able to recognize and deliver different effector proteins, whose expression is also temporally regulated. This may afford the pathogen the opportunity to temporally coordinate the delivery of groups of effector proteins that must exert their function at different times during infection. This is certainly the case in Salmonella enterica, which encodes two TTSS in its pathogenicity islands 1 (SPI-1) and 2 (SPI-2) (Galán, 2001). The SPI-1 TTSS is expressed during Salmonella’s extracellular stage while expression of SPI-2 is induced after internalization. Consequently, the SPI-1 TTSS mediates entry into cells (and the stimulation of transcriptional responses) while the SPI-2 mediates the sculpting of a specific intracellular niche that allows Salmonella to replicate. Each one of these TTSS recognizes specific effector proteins and consequently it has been traditionally assumed that they exert their function in an independent manner. However, it is becoming increasingly clear that there is a much closer functional relationship between these two systems than originally thought. For example, in addition to mediating entry, the SPI-1 TTSS effector proteins divert the S. enterica-containing phagosome from being delivered into lysosomes (Hernandez et al., 2004; Steele-Mortimer et al., 2002). This in turn allows the expression of effectors of the SPI-2 TTSS, which further modulate vesicular trafficking to establish the final replicative niche. In addition, it is becoming clear that some of the TTSS effectors can be recognized by both type III secretion systems. Therefore it appears that “hierarchy” alone may not be sufficient to temporally coordinate the delivery of many effectors that exert their function in a coordinate manner at different times over the infection cycle. Consequently, it seems that Salmonella has evolved two separate TTSS to be able to temporally coordinate the delivery of these effectors.

Yet another mechanism of temporal regulation involves the specific half-life of the effectors within the target cell. For example, as discussed above, the Salmonella TTS effectors SopE and SptP posses opposite activities (GEF and GAP for the same Rho-family GTPases, respectively), and yet they seem to be delivered into cells roughly at the same time. However, their half-lives within cells are quite different. While SopE is rapidly degraded by a ubiquitin-mediated process shortly after its delivery, SptP remains within cells for an extended period of time (Kubori and Galan, 2003). Finally, many bacterial pathogens encode E3 ubiquin ligases, whose targets are unknown (Angot et al., 2007). It is possible that some of these enzymes may be involved in the temporal regulation of the activity of effector proteins delivered by the same TTSS.

Precise localization and functional diversification

It is increasingly clear that effector proteins exert their function at precise locations within the cells, which is central to their function. Yet, remarkably little is known about the mechanisms that restrict the location of an effector to a given compartment. This is in part due to the experimental difficulties in localizing effector proteins after translocation from the bacteria since they are usually delivered in very low amounts. Furthermore, the restrictions in tag choice and position within the effector protein imposed by the protein delivery systems themselves have significantly hampered the development of reliable technologies to visualize in vivo the delivery and location of the effector proteins during infection. Some information on the localization of effectors within cells has been gleaned by transient expression of tagged forms of the effectors. However, as discussed above, these types of experiments may lead to artifacts and therefore should be interpreted with caution. In any case, through limited studies, two common themes are beginning to emerge in the mechanisms of effector protein localization.

One mechanism involves specific domains within the effector protein that serve to target the particular biochemical activity encoded in a different domain of the same effector (Rabin et al., 2006; Schlumberger et al., 2007; Zhang and Barbieri, 2005). This is a common mechanism that directs the localization and the activity of many host cellular proteins. Therefore, it is not surprising that many effectors have domains that share either primary amino acid sequence or structural similarity to domains known to target eukaryotic cell proteins. For example, a family of effector proteins encoded by different pathogens possesses a leucine-rich repeat domain that at least in some cases mediate the localization of their activity to specific locations (Benabdillah et al., 2004; Quezada et al., 2009). Leucine-rich repeat domains, which are in essence “protein-protein” interaction domains, often serve the same purpose in several eukaryotic cell proteins. In addition, some effectors possess nuclear localization signals, which allow them to utilize the nuclear import machinery to reach their final destination (Benabdillah et al., 2004; Szurek B et al., 2002).

Another mechanism of effector localization involves their “post-translocation” modification within the host cell. In this case, the effectors make use of cellular machinery to acquire additional information, which directs them to their specific site of action. For example, the localization of several TTSS effectors from the plant pathogen Pseudomonas syringae is mediated by consensus myristoylation sites, which upon myristoylation inside the host cell, target these effectors to the plasma membrane (Nimchuk et al., 2000). In addition to serving as a signal for degradation, ubiquitination is also used as a targeting signal for some effector proteins. Such is the case of the Salmonella effector SopB, a phosphoinositide phosphatase which, with the same catalyitic activity, mediates bacterial internalization (Zhou et al., 2001), stimulates the production of nitric oxide (Drecktrah et al., 2005), activates Akt (Steele-Mortimer et al., 2000), and modulates vesicular trafficking of the bacterial-containing vacuole (Hernandez et al., 2004; Mallo et al., 2008). Upon translocation from the bacteria, SopB is rapidly mono ubiquitinated (Marcus et al., 2002), which results in its removal from the plasma membrane and its delivery to the Salmonella-containing vacuole (SCV) (Patel et al., 2009). In the absence of ubiquitination, SopB remains at the plasma membrane where it continues to stimulate actin cytoskeleton rearrangments and Akt activation. However, non-ubiquitinated SopB fails to localize to the SCV resulting in defective intracellular bacterial growth (Patel et al., 2009). Thus by exploiting the host ubiquitination machinery, S. Typhimurium not only properly localizes an effector protein, but also broadens the functional repertoire of a virulence factor to maximize its ability to modulate cellular functions.

Functional redundancy

A central element in the design of a robust system is to build functional redundancy. It is therefore not surprising that TTSSs have evolved quite a bit of redundancy, particularly regarding the activities of their effectors. This redundancy takes at least two forms. The simplest form is exemplified by the presence of highly related effectors with apparently similar function. There is, however, a different type of redundancy that is more subtle and consequently often difficult to identify. This type of redundancy involves effectors that have different biochemical activity but target a similar cellular process. For example, Yersinia spp. target Rho-family GTPases to prevent phagocytosis through the activity of at least three different effectors, YopE, YopT, and YpkA (Trosky et al., 2008). However, although all of these effectors inhibit Rho-family GTPases, they do so by different mechanisms. As discussed above, YopE is a GAP that potently inhibits several members of the Rho family. In contrast, YpkA inhibits Rho GTPases by mimicking host guanidine nucleotide dissociation inhibitors (GDIs) thus inhibiting nucleotide exchange in these GTPases. On the other hand, YopT, a cysteine protease, exerts its inhibitory effect by removing the prenylated cysteine from the carboxyl terminus of the Rho GTPases thus releasing them from membranes and preventing their function.

Another form of redundancy in the targeting of Rho GTPases is observed in S. Typhimurium. These bacteria stimulate Rho GTPases to mediate its own uptake into non-phagocytic cells. It does so through the functionally redundant activity of three TTSS effector proteins, SopE, SopE2, and SopB. As discussed above, SopE and SopE2 are GEFs for Rac1, Cdc42, and RhoG (Hardt et al., 1998a; Stender et al., 2000). SopB, on the other hand, is a phosphoinositide phosphatase that activates Rho-family GTPases by stimulating the activity of endogenous exchange factors through the metabolic fluxing of phosphoinositides (Patel and Galan, 2006). Naturally, the built in redundancy in TTSSs adds to the difficulties in the study of the function of individual effector proteins, particularly when the redundancy is not immediately apparent. Indeed, it is a common occurrence that elimination of a single effector protein does not lead to a measurable phenotype, which hampers the study of the role of a specific effector during infection. The identification and elimination of all the redundant effectors is often required to be able to observe a phenotype. However, it is also likely that the lack of phenotypes often observed after the elimination of a single effector may not be due to redundancy but rather to the lack of a specific assay capable of detecting the absence of such an effector. Therefore, the list of “redundant effectors” is likely to diminish as we develop more biological assays and learn more about these systems.

Concluding remarks

The last few years have seen remarkable progress in the understanding of the function of bacterial effector proteins. This knowledge has already revealed common themes in the design and function of this remarkable family of bacterial virulence factors. The identification of the biochemical activities of many effector proteins has not only increased our understanding of these systems but has also potentially uncovered new basic cell biology. The challenge for the future remains gaining a better understanding of the contribution of the different bacterial effectors and the machines that deliver them to the biology and/or pathogenesis of the different bacteria that harbor them. This will necessitate the precise definition of the physiologically relevant targets of the different effectors, an area of research that has lagged behind because of the lack of suitable experimental tools or model systems. There is now firm evidence that indicates that effector proteins delivered by a given bacterium work in concert with one another. Therefore the understanding of the function of a given protein delivery system as a whole will require the definition of the function of all or most of the effector proteins delivered by this particular system. Considering the fact that a given pathogen delivers multiple effector proteins, the task ahead is daunting but not less exciting. It is simply hoped that the next few years will be as exciting and productive as the last few.

Acknowledgments

I thank Heather Carlton, Fangong Du, Stuart Hicks, Veronica Novik, Dirk Hofreuter, Jay Patel, María Lara-Tejero, Heather Scobie, and Stefania Spanó for useful comments and critical review of this manuscript. Work in my laboratory on the subjects discussed in this article has been supported by Grants AI055472 and AI30492 from the National Institutes of Health (to JEG).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • Alouf J. Bacterial protein toxins: an overview. Methods Mol Biol. 2000;145:1–26. [PubMed]
  • Alto N, Shao F, Lazar C, Brost R, Chua G, Mattoo S, McMahon S, Ghosh P, Hughes T, Boone C, et al. Identification of a bacterial type III effector family with G protein mimicry functions. Cell. 2006;124:133–145. [PubMed]
  • Angot A, Peeters N, Lechner E, Vailleau F, Baud C, Gentzbittel L, Sartorel E, Genschik P, Boucher C, Genin S. Ralstonia solanacearum requires F-box-like domain-containing type III effectors to promote disease on several host plants. Proc Natl Acad Sci U S A. 2006;103:14620–14625. [PubMed]
  • Angot A, Vergunst A, Genin S, Peeters N. Exploitation of eukaryotic ubiquitin signaling pathways by effectors translocated by bacterial type III and type IV secretion systems. PLoS Pathog. 2007;3:e3. [PMC free article] [PubMed]
  • Barbieri J. Pseudomonas aeruginosa exoenzyme S, a bifunctional type-III secreted cytotoxin. Int J Med Microbiol. 2000;290:381–387. [PubMed]
  • Benabdillah R, Mota L, Lützelschwab S, Demoinet E, Cornelis G. Identification of a nuclear targeting signal in YopM from Yersinia spp. Microb Pathog. 2004;36:247–261. [PubMed]
  • Bliska JB, Black DS. Inhibition of the Fc receptor-mediated oxidative burst in macrophages by the Yersinia pseudotuberculosis tyrosine phosphatase. Infect Immun. 1995;63:681–685. [PMC free article] [PubMed]
  • Buchwald G, Friebel A, Galán JE, Hardt WD, Wittinghofer A, Scheffzek K. Structural basis for the reversible activation of a Rho protein by the bacterial toxin SopE. EMBO J. 2002;21:3286–3295. [PubMed]
  • Cheng H, Skehan B, Campellone K, Leong J, Rosen M. Structural mechanism of WASP activation by the enterohaemorrhagic E. coli effector EspF(U) Nature. 2008;454:1009–1013. [PMC free article] [PubMed]
  • Christie P, Atmakuri K, Krishnamoorthy V, Jakubowski S, Cascales E. Biogenesis, architecture, and function of bacterial type IV secretion systems. Annu Rev Microbiol. 2005;59:451–485. [PMC free article] [PubMed]
  • Collazo C, Galán JE. Requirement of exported proteins for secretion through the invasion-associated Type III system in Salmonella typhimurium. Infect Immun. 1996;64:3524–3531. [PMC free article] [PubMed]
  • Deng W, Li Y, Hardwidge P, Frey E, Pfuetzner R, Lee S, Gruenheid S, Strynakda N, Puente J, Finlay B. Regulation of type III secretion hierarchy of translocators and effectors in attaching and effacing bacterial pathogens. Infect Immun. 2005;73:2135–2146. [PMC free article] [PubMed]
  • Diao J, Zhang Y, Huibregtse J, Zhou D, Chen J. Crystal structure of SopA, a Salmonella effector protein mimicking a eukaryotic ubiquitin ligase. Nat Struct Mol Biol. 2008;15:65–70. [PubMed]
  • Drecktrah D, Knodler L, Galbraith K, Steele-Mortimer O. The Salmonella SPI1 effector SopB stimulates nitric oxide production long after invasion. Cell Microbiol. 2005:105–113. [PubMed]
  • Du F, Galan J. Selective inhibition of type III secretion activated signaling by the Salmonella effector AvrA. 2009 manuscript submitted. [PMC free article] [PubMed]
  • Filloux A, Hachani A, Bleves S. The bacterial type VI secretion machine: yet another player for protein transport across membranes. Microbiology. 2008;154:1570–1583. [PubMed]
  • Fu Y, Galán JE. The Salmonella spp. protein tyrosine phosphatase SptP is translocated into host cells and disrupts the host-cell cytoskeleton. Mol Microbiol. 1998;27:359–368. [PubMed]
  • Fu Y, Galán JE. A salmonella protein antagonizes Rac-1 and Cdc42 to mediate host-cell recovery after bacterial invasion. Nature. 1999;401:293–297. [PubMed]
  • Galán JE. Salmonella interaction with host cells: Type III Secretion at Work. Annu Rev Cell Dev Biol. 2001;17:53–86. [PubMed]
  • Galan JE, Wolf-Watz H. Protein delivery into eukaryotic cells by type III secretion machines. Nature. 2006;444:567–573. [PubMed]
  • Galyov EE, Hakansson S, Forsberg A, Wolf-Watz H. A secreted protein kinase of Yersinia pseudotuberculosis is an indispensable virulence determinant. Nature. 1993;361:730–732. [PubMed]
  • Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002;82:373–428. [PubMed]
  • Goehring U, Schmidt G, Pederson K, Aktories K, Barbieri J. The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases. J Biol Chem. 1999;274:36369–36372. [PubMed]
  • Guan K, Dixon JE. Protein tyrosine phosphatase activity of an essential virulence determinant in Yersinia. Science. 1990;249:553–556. [PubMed]
  • Hardt W-D, Chen L-M, Schuebel KE, Bustelo XR, Galán JE. Salmonella typhimurium encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells. Cell. 1998a;93:815–826. [PubMed]
  • Hardt W-D, Urlaub H, Galán JE. A target of the centisome 63 type III protein secretion system of Salmonella typhimurium is encoded by a cryptic bacteriophage. Proc Nat Ac Sc USA. 1998b;95:2574–2579. [PubMed]
  • Hernandez LD, Hueffer K, Wenk MR, Galán JE. A Salmonella protein modulates vesicular trafficking by altering phosphoinositide metabolism. Science. 2004;18:1805–1807. [PubMed]
  • Hotson A, Chosed R, Shu H, Orth K, Mudgett M. Xanthomonas type III effector XopD targets SUMO-conjugated proteins in planta. Mol Microbiol. 2003;50:377–389. [PubMed]
  • Izard T, Tran Van Nhieu G, Bois P. Shigella applies molecular mimicry to subvert vinculin and invade host cells. J Cell Biol. 2006;175:465–475. [PMC free article] [PubMed]
  • Janjusevic R, Abramovitch R, Martin G, Stebbins C. A bacterial inhibitor of host programmed cell death defenses is an E3 ubiquitin ligase. Science. 2006;311:222–226. [PubMed]
  • Jones R, Wu H, Wentworth C, L L, Collier-Hyams L, Neish A. Salmonella AvrA Coordinates Suppression of Host Immune and Apoptotic Defenses via JNK Pathway Blockade. Cell Host Microbe. 2008;3:233–244. [PubMed]
  • Kaniga K, Uralil J, Bliska JB, Galán JE. A secreted tyrosine phosphatase with modular effector domains encoded by the bacterial pathogen Salmonella typhimurium. Mol Microbiol. 1996;21:633–641. [PubMed]
  • Kim DW, Lenzen G, Page AL, Legrain P, Sansonetti PJ, Parsot C. The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc Natl Acad Sci U S A. 2005;102:14046–14051. [PubMed]
  • Kubori T, Galan JE. Temporal regulation of salmonella virulence effector function by proteasome-dependent protein degradation. Cell. 2003;115:333–342. [PubMed]
  • Li H, Xu H, Zhou Y, Zhang J, Long C, Li S, Chen S, Zhou J, Shao F. The phosphothreonine lyase activity of a bacterial type III effector family. Science. 2007:1000–1003. [PubMed]
  • Mallo G, Espina M, Smith A, Terebiznik M, Alemán A, Finlay B, Rameh L, Grinstein S, Brumell J. SopB promotes phosphatidylinositol 3-phosphate formation on Salmonella vacuoles by recruiting Rab5 and Vps34. J Cell Biol. 2008;182:741–752. [PMC free article] [PubMed]
  • Marcus S, Knodler L, Finlay B. Salmonella enterica serovar Typhimurium effector SigD/SopB is membrane-associated and ubiquitinated inside host cells. Cell Microbiol. 2002;4:435–446. [PubMed]
  • Mukherjee S, Keitany G, Li Y, Wang Y, Ball H, Goldsmith E, Orth K. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science. 2006;312:1211–1214. [PubMed]
  • Murli S, Watson RO, Galán JE. Role of tyrosine kinases and the tyrosine phosphatase SptP in the interaction of Salmonella with host cells. Cell Microbiol. 2001;3:795–810. [PubMed]
  • Navarro L, Koller A, Nordfelth R, Wolf-Watz H, Taylor S, Dixon J. Identification of a molecular target for the Yersinia protein kinase A. Mol Cell. 2007;26:465–477. [PubMed]
  • Nimchuk Z, Marois E, Kjemtrup S, Leister R, Katagiri F, Dangl J. Eukaryotic fatty acylation drives plasma membrane targeting and enhances function of several type III effector proteins from Pseudomonas syringae. Cell. 2000;101:353–363. [PubMed]
  • Ohlson M, Huang Z, Alto N, Blanc M, Dixon J, Chai J, Miller S. Structure and function of Salmonella SifA indicate that its interactions with SKIP, SseJ, and RhoA family GTPases induce endosomal tubulation. Cell Host Microbe. 2008;4:434–446. [PMC free article] [PubMed]
  • Orth K. Function of the Yersinia effector YopJ. Curr Opin Microbiol. 2002;5:38–43. [PubMed]
  • Patel J, Hueffer K, Lam T, Galán J. Diversification of a Salmonella effector function by ubiquitin-dependent differential localization. Cell. 2009 in press. [PMC free article] [PubMed]
  • Patel JC, Galan JE. Differential activation and function of Rho GTPases during Salmonella-host cell interactions. J Cell Biol. 2006;175:453–463. [PMC free article] [PubMed]
  • Quezada C, Hicks S, Galán J, Stebbins E. A family of Salmonella virulence factors functions as a distinct class of autoregulated E3 ubiquitin ligases. Proc Natl Acad Sci U S A. 2009 Published on line March 9th. [PubMed]
  • Rabin S, Veesenmeyer J, Bieging K, Hauser A. A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells. Infect Immun. 2006;74:2552–2561. [PMC free article] [PubMed]
  • Rohde J, Breitkreutz A, Chenal A, Sansonetti P, Parsot C. Type III Secretion Effectors of the IpaH Family Are E3 Ubiquitin Ligases. Cell, Host Microbe. 2007;1:77–83. [PubMed]
  • Rytkonen A, Poh J, Garmendia J, Boyle C, Thompson A, Liu M, Freemont P, JC H, Holden D, R O. SseL, a Salmonella deubiquitinase required for macrophage killing and virulence. Proc Natl Acad Sci U S A. 2007;104:3502–3507. [PubMed]
  • Schlumberger M, Käppeli R, Wetter M, Müller A, Misselwitz B, Dilling S, Kremer M, Hardt W. Two newly identified SipA domains (F1, F2) steer effector protein localization and contribute to Salmonella host cell manipulation. Mol Microbiol. 2007;65:741–760. [PubMed]
  • Singer A, Rohde J, Lam R, Skarina T, Kagan O, Dileo R, Chirgadze N, Cuff M, Joachimiak A, Tyers M, et al. Structure of the Shigella T3SS effector IpaH defines a new class of E3 ubiquitin ligases. Nat Struct Mol Biol. 2008;15:1293–1301. [PMC free article] [PubMed]
  • Sorg J, Blaylock B, Schneewind O. Secretion signal recognition by YscN, the Yersinia type III secretion ATPase. Proc Natl Acad Sci U S A. 2006;103:16490–16495. [PubMed]
  • Stebbins CE, Galán JE. Modulation of host signaling by a bacterial mimic: structure of the Salmonella effector SptP bound to Rac1. Mol Cell. 2000;6:1449–1460. [PubMed]
  • Stebbins CE, Galán JE. Structural mimicry in bacterial virulence. Nature. 2001;412:701–705. [PubMed]
  • Steele-Mortimer O, Brumell J, Knodler L, Meresse S, Lopez A, Finlay B. The invasion-associated type III secretion system of Salmonella enterica serovar Typhimurium is necessary for intracellular proliferation and vacuole biogenesis in epithelial cells. Cell Microbiol. 2002;4:43–54. [PubMed]
  • Steele-Mortimer O, Knodler L, Marcus S, Scheid M, Goh B, Pfeifer C, Duronio V, Finlay B. Activation of Akt/protein kinase B in epithelial cells by the Salmonella typhimurium effector sigD. J Biol Chem. 2000;275:37718–37724. [PubMed]
  • Stender S, Friebel A, Linder S, Rohde M, Mirold S, Hardt W. Identification of SopE2 from Salmonella typhimurium, a conserved guanine nucleotide exchange factor for Cdc42 of the host cell. Mol Microbiol. 2000;36:1206–1211. [PubMed]
  • Szurek B, Rossier O, Hause G, B U. Type III-dependent translocation of the Xanthomonas AvrBs3 protein into the plant cell. Mol Microbiol. 2002;46:13–23. [PubMed]
  • Tam V, Serruto D, Dziejman M, Brieher W, Mekalanos J. A Type III Secretion System in Vibrio cholerae Translocates a Formin/Spire Hybrid-like Actin Nucleator to Promote Intestinal Colonization. Cell Host and Microbe. 2007;1:95–107. [PubMed]
  • Trosky J, Liverman A, Orth K. Yersinia outer proteins: Yops. Cell Microbiol. 2008;10:557–565. [PubMed]
  • Von Pawel-Rammingen U, Telepnev MV, Schmidt G, Aktories K, Wolf-Watz H, Rosqvist R. GAP activity of the Yersinia YopE cytotoxin specifically targets the Rho pathway: a mechanism for disruption of actin microfilament structure. Mol Microbiol. 2000;36:737–748. [PubMed]
  • Wang D, Roe A, McAteer S, Shipston M, Gally D. Hierarchal type III secretion of translocators and effectors from Escherichia coli O157:H7 requires the carboxy terminus of SepL that binds to Tir. Mol Microbiol. 2008;69:1499–1512. [PubMed]
  • Yarbrough M, Li Y, Kinch L, Grishin N, Ball H, Orth K. AMPylation of Rho GTPases by Vibrio VopS disrupts effector binding and downstream signaling. Science. 2009;323:269–272. [PubMed]
  • Zhang Y, Barbieri J. A leucine-rich motif targets Pseudomonas aeruginosa ExoS within mammalian cells. Infect Immun. 2005;73:7938–7945. [PMC free article] [PubMed]
  • Zhou D, Chen LM, Hernandez L, Shears SB, Galán JE. A Salmonella inositol polyphosphatase acts in conjunction with other bacterial effectors to promote host cell actin cytoskeleton rearrangements and bacterial internalization. Mol Microbiol. 2001;39:248–259. [PubMed]
  • Zhu Y, Li H, Hu L, Wang J, Zhou Y, Pang Z, Liu L, Shao F. Structure of a Shigella effector reveals a new class of ubiquitin ligases. Nat Struct Mol Biol. 2008;15:1302–1308. [PubMed]